Shimla : Pharmaceutical manufacturers in Himachal Pradesh have said the U.S. decision to impose 100% tariffs on branded and patented medicines is unlikely to cause major disruptions, as the state's pharma sector is overwhelmingly focused on generics.

The new duty, set to take effect from October 1, will apply to imported branded and patented drugs. However, industry leaders in Himachal, home to a large concentration of pharma companies, stressed that the state’s drug makers are shielded from the impact. Also Read: US tariffs on pharma sector would be counterproductive for Americans, says Wockhardt Chairman

“More than 95 per cent of pharmaceutical companies located in Baddi, Nalagarh, Kala Amb and Paonta Sahib are engaged in producing generic medicines,” expressed Sanjay Suri, Vice-Chai

See Full Page